FDA Adverse Event Injury Summary report: N

IMPLANTABLE NEUROSTIMULATOR

MDR report key: 13170649 · Received January 5, 2022

Report

Report Number
2182207-2022-00026
Event Type
Injury
Date Received
January 5, 2022
Date of Event
September 5, 2021
Report Date
January 5, 2022
Manufacturer
MEDTRONIC NEUROMODULATION
Product Code
MHY
PMA / PMN Number
P960009
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NO
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 0

THIS VALUE IS THE AVERAGE AGE OF THE PATIENTS REPORTED IN THE ARTICLE AS SPECIFIC PATIENTS COULD NOT BE IDENTIFIED. THIS VALUE REFLECTS THE GENDER OF THE MAJORITY OF THE PATIENTS REPORTED IN THE ARTICLE AS SPECIFIC PATIENTS COULD NOT BE IDENTIFIED. PLEASE NOTE THAT THIS DATE IS BASED OFF OF THE DATE OF PUBLICATION OF THE ARTICLE AS THE EVENT DATES WERE NOT PROVIDED IN THE PUBLISHED LITERATURE. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 0

2021-(B)(6), MD ET. AL. SUBTHALAMIC NUCLEUS STIMULATION IN PARKINSON¿S DISEASE: 5-YEAR EXTENSION STUDY OF A RANDOMIZED TRIAL. DOI: 10.1002/MDC3.13348 WE PERFORMED AN OPEN 5-YEAR EXTENSION STUDY OF A RANDOMIZED TRIAL THAT COMPARED INTRAOPERATIVE VERIFICATION VERSUS MAPPING OF STN USING MICROELECTRODE RECORDINGS. CHANGES FROM PREOPERATIVE TO 5-YEARS OF STN-DBS WERE EVALUATED FOR MOTOR AND NON-MOTOR SYMPTOMS (MDS-UPDRS I-IV), SLEEP DISTURBANCES (PDSS), AUTONOMIC SYMPTOMS (SCOPA-AUT), QUALITY OF LIFE (PDQ-39) AND COGNITION THROUGH A NEUROPSYCHOLOGICAL TEST BATTERY. 3 PATIENTS HAD SURGICAL SITE INFECTIONS WITH HARDWARE EXPLANT WITHIN THE FIRST POSTOPERATIVE YEAR. IT WAS NOT POSSIBLE TO ASCERTAIN SPECIFIC DEVICE INFORMATION FROM THE ARTICLE OR TO MATCH THE REPORTED EVENT WITH ANY PREVIOUSLY REPORTED EVENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1436670 IMPLANTABLE NEUROSTIMULATOR STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINS MHY MEDTRONIC NEUROMODULATION NEU_INS_STIMULATOR

Patients

Seq Age Sex Outcome Treatment
1 63 YR Male Required Intervention